The verdict
Our read at a glance.
Whether a REV-ERB agonist that improved endurance and metabolic markers in mice does anything in humans, and whether it even works the way it is said to work.
- The signal
- The original finding is real: synthetic REV-ERB agonists altered circadian behaviour and metabolism in mice, and REV-ERB biology is a legitimate area of circadian and metabolic research with continuing work on the heart, the colon, hepatic insulin sensitivity and exercise adaptation in muscle. The problem is specific to this molecule. A 2019 study showed SR9009 decreases cell viability, rewires cellular metabolism and alters gene transcription in cells where both REV-ERB-alpha and REV-ERB-beta have been genetically deleted. A 2022 study found SR9009 improved heart function after pressure overload independently of cardiac REV-ERB. Whatever SR9009 is doing, a substantial part of it is not REV-ERB agonism.
- The unknown
- What the off-target activity actually is, and therefore what the safety profile of chronic use would be. There is no published human trial of SR9009 at all, so there is no human efficacy or safety data to weigh against an unexplained mechanism.
- Our read
- The most useful case study on this Watchlist for how a mechanism story outlives its own evidence. The mouse paper was real. The mechanism it was sold on was then shown not to be required for its effects, and no one has taken it into a human trial in over a decade. Buying it is buying an unidentified pharmacology.
The mechanism
How it works.
REV-ERB-alpha and REV-ERB-beta are nuclear receptors that act as repressors inside the circadian clock, switching off target genes at particular times of day and, in the process, shaping how muscle and liver handle fuel. SR9009 was designed as a synthetic agonist of those receptors: push REV-ERB activity up, and in mice you get changes in circadian behaviour, oxygen consumption and lipid handling that resemble some of what training does. The reason this memo sits at Preclinical rather than being an exciting early lead is what happened when the mechanism was tested directly. In cells engineered to lack both REV-ERB proteins, SR9009 still changed viability, metabolism and gene transcription, and in a cardiac pressure-overload model it still helped without cardiac REV-ERB. The compound has effects. They are simply not, or not only, the effects it is named for.
Safety & regulatory boundary
The consequential part.
Not approved anywhere, not a lawful dietary supplement ingredient, and never taken into human trials. Prohibited in sport. Reported oral bioavailability in rodents is poor, which makes the dosing regimens circulated for oral human use pharmacologically incoherent even before the mechanism question. Product sold under this name is a research chemical of unverified identity.
What's next
What we're watching.
Any characterisation of the off-target activity, and any REV-ERB-targeting compound that enters real human development, which would be the honest test of the underlying idea.
Context
Why this is discussed.
The 2012 mouse result was genuinely striking, it was reported everywhere as exercise in a pill, and the compound has been sold on that headline ever since.
The evidence base
9 cited references.
Indexed literature (PubMed)9
Song S et al. · Circulation · 2022
Cho H et al. · Nature · 2012
Solt LA et al. · Nature · 2012
Dierickx P et al. · Proc Natl Acad Sci U S A · 2019
Wang S et al. · Nat Commun · 2018
Li H et al. · Front Cardiovasc Med · 2022
Ding G et al. · Nature · 2021
Liu J et al. · Nat Commun · 2025
Shen W et al. · Theranostics · 2020
Keep reading